Lubrizol’s Apisolex polymer excipient has won Silver in the Drug Delivery Empowerment category at the 2026 CPhI China Pharma Excipients Awards.
The recognition honours innovative excipient technologies that advance drug delivery, improve bioavailability and demonstrate strong market potential.
Apisolexpolymer was selected from a field of more than 100 nominees across all award categories and recognised for addressing one of the most persistent formulation challenges in drug development.
The injectable excipient can enhance the solubility of poorly soluble BCS Class II and IV APIs by up to 50,000-fold, helping overcome a critical barrier in a pipeline where approximately 60% of candidate drugs face solubility limitations.
Lubrizol said the latest recognition adds to Apisolex polymer’s growing track record of industry honours, including CPhI China’s Pharma Excipients Award in the Advanced Technology category in 2023 and a Finished Formulation award at CPhI Barcelona in 2023.
In addition, the polymer received a Celebration Award in the Pharma Excipients category at CPhI China last year.
"Being recognised by CPhI, the industry's primary showcase of pharmaceutical innovation, underscores Lubrizol’s continued commitment to next-generation excipient technologies that expand formulation possibilities and improve drug delivery," said Kevin Song, Senior Director, Global Nutraceutical and Pharmaceutical Businesses.
